Dystroglycanopathies: Coming into focus

Current Opinion in Genetics and Development

Volumn 21, Issue 3, 2011, Pages 278-285

  Godfrey, Caroline ^a   Foley, A Reghan ^a   Clement, Emma ^a   Muntoni, Francesco ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA DYSTROGLYCAN; DOLICHYL PHOSPHATE MANNOSYLTRANSFERASE POLYPEPTIDE 2; DOLICHYL PHOSPHATE MANNOSYLTRANSFERASE POLYPEPTIDE 3; FUKUTIN; FUKUTIN RELATED PROTEIN; GLYCOSYLTRANSFERASE; LIKE GLYCOSYLTRANSFERASE; MANNOSYLTRANSFERASE; N ACETYLGLUCOSAMINYLTRANSFERASE; PROTEIN O LINKED MANNOSE BETA 1,2 N ACETYLGLUCOSAMINYLTRANSFERASE; PROTEIN O MANNOSYLTRANSFERASE 1; PROTEIN O MANNOSYLTRANSFERASE 2; UNCLASSIFIED DRUG;

CONGENITAL DISORDER OF GLYCOSYLATION; DYSTROGLYCANOPATHY; FKRP GENE; FKTN GENE; FUKUYAMA CONGENITAL MUSCULAR DYSTROPHY; GENE IDENTIFICATION; GENE MUTATION; GENOTYPE PHENOTYPE CORRELATION; GLYCOBIOLOGY; HUMAN; LARGE GENE; LIMB GIRDLE MUSCULAR DYSTROPHY; MUSCLE EYE BRAIN DISEASE; MUSCULAR DYSTROPHY; NONHUMAN; POMGNT1 GENE; POMT1 GENE; POMT2 GENE; PRIORITY JOURNAL; PROTEIN GLYCOSYLATION; REVIEW; WALKER WARBURG SYNDROME;

ANIMALS; CENTRAL NERVOUS SYSTEM; DISEASE MODELS, ANIMAL; DYSTROGLYCANS; EYE; GENETIC ASSOCIATION STUDIES; GLYCOSYLATION; GLYCOSYLTRANSFERASES; HUMANS; MICE; MUSCULAR DYSTROPHIES; POLYSACCHARIDES; ZEBRAFISH;

EID: 79957622998     PISSN: 0959437X     EISSN: 18790380     Source Type: Journal    
DOI: 10.1016/j.gde.2011.02.001     Document Type: Review

References (48)

1. Beltran-Valero de Bernabe D., Currier S., Steinbrecher A., Celli J., van Beusekom E., van der Zwaag B., Kayserili H., Merlini L., Chitayat D., Dobyns W.B., et al. Mutations in the O-mannosyltransferase gene POMT1 give rise to the severe neuronal migration disorder Walker-Warburg syndrome. Am J Hum Genet 2002, 71:1033-1043.
2. Kobayashi K., Nakahori Y., Miyake M., Matsumura K., Kondo-Iida E., Nomura Y., Segawa M., Yoshioka M., Saito K., Osawa M., et al. An ancient retrotransposal insertion causes Fukuyama-type congenital muscular dystrophy. Nature 1998, 394:388-392.
3. Yoshida A., Kobayashi K., Manya H., Taniguchi K., Kano H., Mizuno M., Inazu T., Mitsuhashi H., Takahashi S., Takeuchi M., et al. Muscular dystrophy and neuronal migration disorder caused by mutations in a glycosyltransferase, POMGnT1. Dev Cell 2001, 1:717-724.
4. van Reeuwijk J., Janssen M., van den Elzen C., Beltran-Valero de Bernabe D., Sabatelli P., Merlini L., Boon M., Scheffer H., Brockington M., Muntoni F., et al. POMT2 mutations cause alpha-dystroglycan hypoglycosylation and Walker-Warburg syndrome. J Med Genet 2005, 42:907-912.
5. Brockington M., Blake D.J., Prandini P., Brown S.C., Torelli S., Benson M.A., Ponting C.P., Estournet B., Romero N.B., Mercuri E., et al. Mutations in the fukutin-related protein gene (FKRP) cause a form of congenital muscular dystrophy with secondary laminin alpha2 deficiency and abnormal glycosylation of alpha-dystroglycan. Am J Hum Genet 2001, 69:1198-1209.
6. Michele D.E., Barresi R., Kanagawa M., Saito F., Cohn R.D., Satz J.S., Dollar J., Nishino I., Kelley R.I., Somer H., et al. Post-translational disruption of dystroglycan-ligand interactions in congenital muscular dystrophies. Nature 2002, 418:417-422.
7. Lefeber D.J., Schonberger J., Morava E., Guillard M., Huyben K.M., Verrijp K., Grafakou O., Evangeliou A., Preijers F.W., Manta P., et al. Deficiency of Dol-P-Man synthase subunit DPM3 bridges the congenital disorders of glycosylation with the dystroglycanopathies. Am J Hum Genet 2009, 85:76-86.
8. Longman C., Brockington M., Torelli S., Jimenez-Mallebrera C., Kennedy C., Khalil N., Feng L., Saran R.K., Voit T., Merlini L., et al. Mutations in the human LARGE gene cause MDC1D, a novel form of congenital muscular dystrophy with severe mental retardation and abnormal glycosylation of alpha-dystroglycan. Hum Mol Genet 2003, 12:2853-2861.
9. Bouchet C., Gonzales M., Vuillaumier-Barrot S., Devisme L., Lebizec C., Alanio E., Bazin A., Bessieres-Grattagliano B., Bigi N., Blanchet P., et al. Molecular heterogeneity in fetal forms of type II lissencephaly. Hum Mutat 2007, 28:1020-1027.
10. Manzini M.C., Gleason D., Chang B.S., Hill R.S., Barry B.J., Partlow J.N., Poduri A., Currier S., Galvin-Parton P., Shapiro L.R., et al. Ethnically diverse causes of Walker-Warburg syndrome (WWS): FCMD mutations are a more common cause of WWS outside of the Middle East. Hum Mutat 2008, 29:E231-E241.
11. Mercuri E., Messina S., Bruno C., Mora M., Pegoraro E., Comi G.P., D'Amico A., Aiello C., Biancheri R., Berardinelli A., et al. Congenital muscular dystrophies with defective glycosylation of dystroglycan: a population study. Neurology 2009, 72:1802-1809.
12. Godfrey C., Clement E., Mein R., Brockington M., Smith J., Talim B., Straub V., Robb S., Quinlivan R., Feng L., et al. Refining genotype phenotype correlations in muscular dystrophies with defective glycosylation of dystroglycan. Brain 2007, 130:2725-2735.
13. Jimenez-Mallebrera C., Torelli S., Feng L., Kim J., Godfrey C., Clement E., Mein R., Abbs S., Brown S.C., Campbell K.P., et al. A comparative study of alpha-dystroglycan glycosylation in dystroglycanopathies suggests that the hypoglycosylation of alpha-dystroglycan does not consistently correlate with clinical severity. Brain Pathol 2009, 19:596-611.
14. Clement E., Mercuri E., Godfrey C., Smith J., Robb S., Kinali M., Straub V., Bushby K., Manzur A., Talim B., et al. Brain involvement in muscular dystrophies with defective dystroglycan glycosylation. Ann Neurol 2008, 64:573-582.
15. Messina S., Tortorella G., Concolino D., Spano M., D'Amico A., Bruno C., Santorelli F.M., Mercuri E., Bertini E. Congenital muscular dystrophy with defective alpha-dystroglycan, cerebellar hypoplasia, and epilepsy. Neurology 2009, 73:1599-1601.
16. Cao W., Henry M.D., Borrow P., Yamada H., Elder J.H., Ravkov E.V., Nichol S.T., Compans R.W., Campbell K.P., Oldstone M.B. Identification of alpha-dystroglycan as a receptor for lymphocytic choriomeningitis virus and Lassa fever virus. Science 1998, 282:2079-2081.
17. Rambukkana A., Yamada H., Zanazzi G., Mathus T., Salzer J.L., Yurchenco P.D., Campbell K.P., Fischetti V.A. Role of alpha-dystroglycan as a Schwann cell receptor for Mycobacterium leprae. Science 1998, 282:2076-2079.
18. Singh J., Itahana Y., Knight-Krajewski S., Kanagawa M., Campbell K.P., Bissell M.J., Muschler J. Proteolytic enzymes and altered glycosylation modulate dystroglycan function in carcinoma cells. Cancer Res 2004, 64:6152-6159.
19. Bao X., Kobayashi M., Hatakeyama S., Angata K., Gullberg D., Nakayama J., Fukuda M.N., Fukuda M. Tumor suppressor function of laminin-binding alpha-dystroglycan requires a distinct beta3-N-acetylglucosaminyltransferase. Proc Natl Acad Sci USA 2009, 106:12109-12114.
20. Peyrard M., Seroussi E., Sandberg-Nordqvist A.C., Xie Y.G., Han F.Y., Fransson I., Collins J., Dunham I., Kost-Alimova M., Imreh S., et al. The human LARGE gene from 22q12.3-q13.1 is a new, distinct member of the glycosyltransferase gene family. Proc Natl Acad Sci USA 1999, 96:598-603.
21. Saito F., Blank M., Schroder J., Manya H., Shimizu T., Campbell K.P., Endo T., Mizutani M., Kroger S., Matsumura K. Aberrant glycosylation of alpha-dystroglycan causes defective binding of laminin in the muscle of chicken muscular dystrophy. FEBS Lett 2005, 579:2359-2363.
22. Ervasti J.M., Campbell K.P. Membrane organization of the dystrophin-glycoprotein complex. Cell 1991, 66:1121-1131.
23. Matsumoto H., Yoshizawa M.H., Sasazaki K., Fujiwara S., Kikuchi A.T. Pinpointing the candidate region for muscular dystrophy in chickens with an abnormal muscle gene. Anim Sci J 2007, 78:476-483.
24. Matsumoto H., Maruse H., Inaba Y., Yoshizawa K., Sasazaki S., Fujiwara A., Nishibori M., Nakamura A., Takeda S., Ichihara N., et al. The ubiquitin ligase gene (WWP1) is responsible for the chicken muscular dystrophy. FEBS Lett 2008, 582:2212-2218.
25. Barresi R., Campbell K.P. Dystroglycan: from biosynthesis to pathogenesis of human disease. J Cell Sci 2006, 119:199-207.
26. Smalheiser N.R., Schwartz N.B. Cranin: a laminin-binding protein of cell membranes. Proc Natl Acad Sci USA 1987, 84:6457-6461.
27. Michele D.E., Campbell K.P. Dystrophin-glycoprotein complex: post-translational processing and dystroglycan function. J Biol Chem 2003, 278:15457-15460.
28. Brown S.C., Torelli S., Brockington M., Yuva Y., Jimenez C., Feng L., Anderson L., Ugo I., Kroger S., Bushby K., et al. Abnormalities in alpha-dystroglycan expression in MDC1C and LGMD2I muscular dystrophies. Am J Pathol 2004, 164:727-737.
29. Ibraghimov-Beskrovnaya O., Milatovich A., Ozcelik T., Yang B., Koepnick K., Francke U., Campbell K.P. Human dystroglycan: skeletal muscle cDNA, genomic structure, origin of tissue specific isoforms and chromosomal localization. Hum Mol Genet 1993, 2:1651-1657.
30. Matsumura K., Chiba A., Yamada H., Fukuta-Ohi H., Fujita S., Endo T., Kobata A., Anderson L.V., Kanazawa I., Campbell K.P., et al. A role of dystroglycan in schwannoma cell adhesion to laminin. J Biol Chem 1997, 272:13904-13910.
31. Toda T., Kobayashi K., Takeda S., Sasaki J., Kurahashi H., Kano H., Tachikawa M., Wang F., Nagai Y., Taniguchi K., et al. Fukuyama-type congenital muscular dystrophy (FCMD) and alpha-dystroglycanopathy. Congenit Anom (Kyoto) 2003, 43:97-104.
32. Yoshida-Moriguchi T., Yu L., Stalnaker S.H., Davis S., Kunz S., Madson M., Oldstone M.B., Schachter H., Wells L., Campbell K.P. O-mannosyl phosphorylation of alpha-dystroglycan is required for laminin binding. Science 2010, 327:88-92.
33. Nilsson J., Nilsson J., Larson G., Grahn A. Characterization of site-specific O-glycan structures within the mucin-like domain of alpha-dystroglycan from human skeletal muscle. Glycobiology 2010, 20:1160-1169.
34. Stalnaker S.H., Hashmi S., Lim J.M., Aoki K., Porterfield M., Gutierrez-Sanchez G., Wheeler J., Ervasti J.M., Bergmann C., Tiemeyer M., et al. Site mapping and characterization of O-glycan structures on alpha-dystroglycan isolated from rabbit skeletal muscle. J Biol Chem 2010, 285:24882-24891.
35. Hewitt J.E. Abnormal glycosylation of dystroglycan in human genetic disease. Biochim Biophys Acta 2009, 1792:853-861.
36. Thornhill P., Bassett D., Lochmuller H., Bushby K., Straub V. Developmental defects in a zebrafish model for muscular dystrophies associated with the loss of fukutin-related protein (FKRP). Brain 2008, 131:1551-1561.
37. Kawahara G., Guyon J.R., Nakamura Y., Kunkel L.M. Zebrafish models for human FKRP muscular dystrophies. Hum Mol Genet 2010, 19:623-633.
38. Ackroyd M.R., Skordis L., Kaluarachchi M., Godwin J., Prior S., Fidanboylu M., Piercy R.J., Muntoni F., Brown S.C. Reduced expression of fukutin related protein in mice results in a model for fukutin related protein associated muscular dystrophies. Brain 2009, 132:439-451.
39. Chan Y.M., Keramaris-Vrantsis E., Lidov H.G., Norton J.H., Zinchenko N., Gruber H.E., Thresher R., Blake D.J., Ashar J., Rosenfeld J., et al. Fukutin-related protein is essential for mouse muscle, brain and eye development and mutation recapitulates the wide clinical spectrums of dystroglycanopathies. Hum Mol Genet 2010, 19:3995-4006.
40. Barresi R., Michele D.E., Kanagawa M., Harper H.A., Dovico S.A., Satz J.S., Moore S.A., Zhang W., Schachter H., Dumanski J.P., et al. LARGE can functionally bypass alpha-dystroglycan glycosylation defects in distinct congenital muscular dystrophies. Nat Med 2004, 10:696-703.
41. Brockington M., Torelli S., Sharp P.S., Liu K., Cirak S., Brown S.C., Wells D.J., Muntoni F. Transgenic overexpression of LARGE induces alpha-dystroglycan hyperglycosylation in skeletal and cardiac muscle. PLoS One 2010, 5:e14434.
42. Clement E.M., Godfrey C., Tan J., Brockington M., Torelli S., Feng L., Brown S.C., Jimenez-Mallebrera C., Sewry C.A., Longman C., et al. Mild POMGnT1 mutations underlie a novel limb-girdle muscular dystrophy variant. Arch Neurol 2008, 65:137-141.
43. Murakami T., Hayashi Y.K., Noguchi S., Ogawa M., Nonaka I., Tanabe Y., Ogino M., Takada F., Eriguchi M., Kotooka N., et al. Fukutin gene mutations cause dilated cardiomyopathy with minimal muscle weakness. Ann Neurol 2006, 60:597-602.
44. Van Geet C., Jaeken J., Freson K., Lenaerts T., Arnout J., Vermylen J., Hoylaerts M.F. Congenital disorders of glycosylation type Ia and IIa are associated with different primary haemostatic complications. J Inherit Metab Dis 2001, 24:477-492.
45. Mercuri E., Topaloglu H., Brockington M., Berardinelli A., Pichiecchio A., Santorelli F., Rutherford M., Talim B., Ricci E., Voit T., et al. Spectrum of brain changes in patients with congenital muscular dystrophy and FKRP gene mutations. Arch Neurol 2006, 63:251-257.
46. Balci B., Uyanik G., Dincer P., Gross C., Willer T., Talim B., Haliloglu G., Kale G., Hehr U., Winkler J., et al. An autosomal recessive limb girdle muscular dystrophy (LGMD2) with mild mental retardation is allelic to Walker-Warburg syndrome (WWS) caused by a mutation in the POMT1 gene. Neuromuscul Disord 2005, 15:271-275.
47. Brockington M., Yuva Y., Prandini P., Brown S.C., Torelli S., Benson M.A., Herrmann R., Anderson L.V., Bashir R., Burgunder J.M., et al. Mutations in the fukutin-related protein gene (FKRP) identify limb girdle muscular dystrophy 2I as a milder allelic variant of congenital muscular dystrophy MDC1C. Hum Mol Genet 2001, 10:2851-2859.
48. Godfrey C., Escolar D., Brockington M., Clement E.M., Mein R., Jimenez-Mallebrera C., Torelli S., Feng L., Brown S.C., Sewry C.A., et al. Fukutin gene mutations in steroid-responsive limb girdle muscular dystrophy. Ann Neurol 2006, 60:603-610.